



(51) International Patent Classification:

C07C 233/83 (2006.01) **C07D 213/64** (2006.01)
C07C 233/87 (2006.01) **C07D 277/50** (2006.01)
C07C 255/41 (2006.01) **C07D 295/192** (2006.01)
C07C 311/06 (2006.01) **A61K 31/18** (2006.01)
C07C 311/13 (2006.01) **A61P 21/00** (2006.01)

(21) International Application Number:

PCT/GB2014/053626

(22) International Filing Date:

5 December 2014 (05.12.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1321601.5 6 December 2013 (06.12.2013) GB

(71) Applicant: **CANBEX THERAPEUTICS LIMITED**
 [GB/GB]; The Network Building, 97 Tottenham Court
 Road, London, Greater London W1T 4TP (GB).

(72) Inventor: **SELWOOD, David**; 50 Fordwich Road, Wel-
 wyn Garden City, Hertfordshire AL8 6EY (GB).

(74) Agent: **CLYDE-WATSON, Zoe**; 120 Holborn, London,
 Greater London EC1N 2DY (GB).


(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS



I

(57) Abstract: The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof: (I) wherein: n is 0 or 1; R₁ is selected from H, alkyl and aralkyl, wherein said alkyl and aralkyl groups may be optionally substituted by one or more OH groups; X is a group selected from -C≡C-(CH₂)_p-; -C(R⁵)=C(R⁶)-(CH₂)_q-; and -C(R⁵)(R⁶)C(R⁷)(R⁸)-(CH₂)_r-; where each of R⁵, R⁶, R⁷ and R⁸ is independently H or alkyl, and each of p, q and r is independently 1, 2, 3, 4 or 5; Y is a group selected from: CN; COOR²; CONR³R⁴; SO₂NR⁹R¹⁰; NR¹²COR¹³; NR¹⁴SO₂R¹⁵; and a heterocyclic group selected from oxadiazolyl, thiazolyl, iso-thiazolyl, oxazolyl, iso-oxazolyl, pyrazolyl and imidazolyl; where each of R², R³ and R⁴ is independently H or alkyl; or R³ and R⁴ are linked, together with the nitrogen to which they are attached, to form a 5 or 6-membered heterocycloalkyl or heterocycloalkenyl group, said heterocycloalkyl or heterocycloalkenyl group optionally containing one or more further groups selected from O, N, CO and S, and where each of R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ is independently H or alkyl. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, pain, or for controlling spasticity or tremors, for example, spasticity in MS.